Characterization of tumor size changes over time from the phase 3 study of lenvatinib in thyroid cancer

Bruce Robinson, Martin Schlumberger, Lori J. Wirth, Corina E. Dutcus, James Song, Matthew H. Taylor, Sung Bae Kim, Monika K. Krzyzanowska, Jaume Capdevila, Steven I. Sherman, Makoto Tahara

Research output: Contribution to journalArticlepeer-review

64 Scopus citations


Context: Lenvatinib improved the progression-free survival (PFS) and overall response rate of patients with radioiodine-refractory differentiated thyroid cancer vs placebo in the Phase 3 Study of (E7080) Lenvatinib in Differentiated Cancer of the Thyroid (SELECT). Objective: The objective of the study was to characterize tumor size changes with lenvatinib treatment. Design: SELECT was a phase 3, randomized, double-blind, multicenter study. Setting: In this clinical trial,tumorassessments of lenvatinib (n=261)andplacebo-treated (n=131) patients were performed by independent radiological review per Response Evaluation Criteria in Solid Tumors version, 1.1 at 8-week intervals. Patients: Patients with complete or partial response were defined as responders to lenvatinib (n= 169). Of the 92 nonresponders, 76 had at least one postbaseline tumor assessment and were included in this analysis. Interventions: Lenvatinib (24mgonce daily) or placebo in 28-day cycles until unacceptable toxicity, disease progression, or death. MainOutcomeMeasures: Thiswasanexploratory analysis of keyendpoints from SELECT, including PFS, overall response rate, and tumor reduction. Results: The medianmaximumpercentage change in tumor size was-42.9%for patients receiving lenvatinib (responders,-51.9%; nonresponders,-20.2%). Tumor size reduction was most pronounced at first assessment (median,-24.7%at 8wk after randomization); thereafter, the rate of change was slower but continuous (-1.3%per mo). In a multivariate model, percentage change in tumor size at the first assessment was a marginally significant positive predictor for PFS P= .06). Conclusions: The change in tumor size conferred by lenvatinib was characterized by two phases: an initial, rapid decline, followed by slower, continuous shrinkage. (J Clin Endocrinol Metab 101: 4103-4109, 2016).

Original languageEnglish (US)
Pages (from-to)4103-4109
Number of pages7
JournalJournal of Clinical Endocrinology and Metabolism
Issue number11
StatePublished - Nov 2016

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Biochemistry
  • Endocrinology
  • Clinical Biochemistry
  • Biochemistry, medical


Dive into the research topics of 'Characterization of tumor size changes over time from the phase 3 study of lenvatinib in thyroid cancer'. Together they form a unique fingerprint.

Cite this